Trials / Unknown
UnknownNCT04297293
Ramosetron OD Tablet and Postdischarge Nausea and Vomiting
Effects of Ramosetron Orally Disintegrating Tablet on the Prophylaxis of Postdischarge Nausea and Vomiting in High-risk Patients Undergoing Day Surgery Under General Anesthesia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 138 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Postoperative nausea and vomiting after general anesthesia is one of the common anesthetic complications. If the patient is discharged from the hospital after surgery, proper treatment may be delayed or impossible if nausea and vomiting occurred. Thus, it is necessary to prevent these symptoms beforehand. Patients who underwent day-surgery will be treated with prophylactic ramosetron orally disintegrating tablets to determine whether the frequency of nausea and vomiting is decreased when the patient returned home after discharge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ramosetron | Ramosetron orally disintegrating tablet 0.1 mg is administered after discharge (postoperative day 1 and day 2) |
Timeline
- Start date
- 2020-05-12
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
- First posted
- 2020-03-05
- Last updated
- 2021-12-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04297293. Inclusion in this directory is not an endorsement.